- Home
- GSIW vs RLMD Comparison
GSIW vs RLMD Comparison
Compare GSIW & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- RLMD
- Stock Information
- Founded
- GSIW 2016
- RLMD 2004
- Country
- GSIW Hong Kong
- RLMD United States
- Employees
- GSIW N/A
- RLMD N/A
- Industry
- GSIW
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- RLMD Health Care
- Exchange
- GSIW Nasdaq
- RLMD Nasdaq
- Market Cap
- GSIW 12.3M
- RLMD 11.5M
- IPO Year
- GSIW 2023
- RLMD N/A
- Fundamental
- Price
- GSIW $0.48
- RLMD $0.30
- Analyst Decision
- GSIW
- RLMD Hold
- Analyst Count
- GSIW 0
- RLMD 4
- Target Price
- GSIW N/A
- RLMD $4.25
- AVG Volume (30 Days)
- GSIW 91.3K
- RLMD 382.7K
- Earning Date
- GSIW 12-31-2024
- RLMD 03-27-2025
- Dividend Yield
- GSIW N/A
- RLMD N/A
- EPS Growth
- GSIW N/A
- RLMD N/A
- EPS
- GSIW N/A
- RLMD N/A
- Revenue
- GSIW $1,313,795.00
- RLMD N/A
- Revenue This Year
- GSIW N/A
- RLMD N/A
- Revenue Next Year
- GSIW N/A
- RLMD N/A
- P/E Ratio
- GSIW N/A
- RLMD N/A
- Revenue Growth
- GSIW N/A
- RLMD N/A
- 52 Week Low
- GSIW $0.43
- RLMD $0.24
- 52 Week High
- GSIW $12.30
- RLMD $5.09
- Technical
- Relative Strength Index (RSI)
- GSIW 47.04
- RLMD 50.05
- Support Level
- GSIW $0.45
- RLMD $0.26
- Resistance Level
- GSIW $0.52
- RLMD $0.32
- Average True Range (ATR)
- GSIW 0.03
- RLMD 0.02
- MACD
- GSIW 0.00
- RLMD 0.00
- Stochastic Oscillator
- GSIW 58.82
- RLMD 67.34
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.